FindTrial
Sign In

Administration study for Revolade to healthy Japanese adult males

Administration study for Revolade to healthy Japanese adult males

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080222265
Enrollment
3
Registered
2013-10-28
Start date
2013-10-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : Revolade INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigati

Sponsors

Mitsubishi chemical Medience Corporation
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Weight: more than 50 kg, BMI :more than 17.6 and below 26.4 Blood platelet count: less than 200,000 mcg/L

Exclusion criteria

Exclusion criteria: -Hypersensitivity to drugs, -A history of alcoholism or drug addiction, -Ethical or OTC pharmaceuticals administered within two weeks before scheduled administration of the study drug, -Supplement, grapefruit or its products, or foods containing Hypericum perforatum consumed within one week before scheduled administration of the study drug, and - Not less than 200 mL of blood is collected within 30 days or not less than 400 mL of blood is collected within 90 days before scheduled administration of the study drug.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026